IGC Pharma Advances In Alzheimer’s Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1
–News Direct– By Faith Ashmore, Benzinga Alzheimer's disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact of Alzheimers disease makes it a major healthcare challenge. In 2023, Alzheimers and other types of dementia were projected to cost the U.S. $345 […]